Comparative Pharmacology
Head-to-head clinical analysis: VANCOMYCIN HCL versus VANCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANCOMYCIN HCL versus VANCOR.
VANCOMYCIN HCL vs VANCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing cross-linking and polymerization.
Inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation.
15-20 mg/kg IV every 8-12 hours (max 2 g/dose) for serious infections; target trough 15-20 mcg/mL.
Vancomycin 15-20 mg/kg IV every 8-12 hours, with target trough 10-20 mcg/mL; for serious infections, consider loading dose 25-30 mg/kg IV.
None Documented
None Documented
4-6 hours in normal renal function; prolonged to 7-9 days in anuria/ESRD, necessitating dosing adjustments
Terminal elimination half-life is 4-6 hours in adults with normal renal function; can extend to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Primarily renal (90-95% unchanged via glomerular filtration), with minor biliary/fecal (<5%)
Renal excretion of unchanged drug accounts for 80-90% of clearance via glomerular filtration; minor biliary excretion (<5%) and fecal elimination (<5%).
Category A/B
Category C
Glycopeptide Antibiotic
Glycopeptide Antibiotic